CA2616196C - A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor - Google Patents

A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor Download PDF

Info

Publication number
CA2616196C
CA2616196C CA2616196A CA2616196A CA2616196C CA 2616196 C CA2616196 C CA 2616196C CA 2616196 A CA2616196 A CA 2616196A CA 2616196 A CA2616196 A CA 2616196A CA 2616196 C CA2616196 C CA 2616196C
Authority
CA
Canada
Prior art keywords
pyridin
methyl
quinolin
pyrrolo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2616196A
Other languages
English (en)
French (fr)
Other versions
CA2616196A1 (en
Inventor
Sreenivasa Reddy Mundla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2616196A1 publication Critical patent/CA2616196A1/en
Application granted granted Critical
Publication of CA2616196C publication Critical patent/CA2616196C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2616196A 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor Expired - Fee Related CA2616196C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70164105P 2005-07-22 2005-07-22
US60/701,641 2005-07-22
PCT/US2006/025377 WO2007018818A1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Publications (2)

Publication Number Publication Date
CA2616196A1 CA2616196A1 (en) 2007-02-15
CA2616196C true CA2616196C (en) 2012-08-21

Family

ID=37450942

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2616196A Expired - Fee Related CA2616196C (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Country Status (16)

Country Link
US (1) US7872020B2 (enExample)
EP (1) EP1910370B1 (enExample)
JP (1) JP5242391B2 (enExample)
BR (1) BRPI0613639A2 (enExample)
CA (1) CA2616196C (enExample)
DK (1) DK1910370T3 (enExample)
ES (1) ES2542425T3 (enExample)
HR (1) HRP20150474T1 (enExample)
HU (1) HUE025209T2 (enExample)
IL (1) IL188181A (enExample)
MX (1) MX2008001020A (enExample)
PL (1) PL1910370T3 (enExample)
PT (1) PT1910370E (enExample)
RS (1) RS53999B1 (enExample)
SI (1) SI1910370T1 (enExample)
WO (1) WO2007018818A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
CN103764655B (zh) * 2011-07-13 2017-04-12 Sk化学公司 作为alk5和／或alk4抑制剂的经2‑吡啶基取代的咪唑
US20150289795A1 (en) 2012-11-12 2015-10-15 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
CN105358677B (zh) 2013-03-14 2018-06-15 布里格海姆妇女医院公司 用于上皮干细胞扩增和培养的组合物和方法
KR102493376B1 (ko) 2014-09-03 2023-01-27 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017106291A1 (en) 2015-12-15 2017-06-22 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
WO2018165979A1 (zh) * 2017-03-17 2018-09-20 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1397364E (pt) 2001-05-24 2007-10-22 Lilly Co Eli Novos derivados de pirrole como agentes farmacêuticos
CA2506799A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles

Also Published As

Publication number Publication date
PL1910370T3 (pl) 2015-09-30
HRP20150474T1 (xx) 2015-06-05
EP1910370A1 (en) 2008-04-16
RS53999B1 (sr) 2015-10-30
BRPI0613639A2 (pt) 2012-02-22
US7872020B2 (en) 2011-01-18
SI1910370T1 (sl) 2015-06-30
ES2542425T3 (es) 2015-08-05
JP2009502780A (ja) 2009-01-29
PT1910370E (pt) 2015-06-30
CA2616196A1 (en) 2007-02-15
MX2008001020A (es) 2008-03-25
JP5242391B2 (ja) 2013-07-24
IL188181A (en) 2014-05-28
EP1910370B1 (en) 2015-04-22
HUE025209T2 (en) 2016-03-29
IL188181A0 (en) 2008-03-20
US20100120854A1 (en) 2010-05-13
WO2007018818A1 (en) 2007-02-15
DK1910370T3 (en) 2015-06-08

Similar Documents

Publication Publication Date Title
CA2616196C (en) A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
EP3037424B1 (en) Novel quinoline-substituted compound
AU2016288204B2 (en) Inhibitors of EGFR and methods of use thereof
AU2015330506B2 (en) EGFR inhibitor, and preparation and application thereof
AU2008252380B2 (en) Quinazolin-oxime derivatives as Hsp90 inhibitors
SK9622000A3 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
JP2015180679A (ja) ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
CZ139097A3 (cs) 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi
AU2008208801A1 (en) Purine derivatives
EP2985277A1 (en) Dipyrromethene crystal and method for manufacturing same
AU2012291041A1 (en) Uracil derivative and use thereof for medical purposes
HUE029343T2 (en) Quinolylpyrrolo-pyrimidyl fused ring compounds and salts thereof
CA3149846A1 (en) Quinoline derivatives as protein kinase inhibitors
AU2018337138B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
UA54449C2 (uk) 3-заміщені похідні піридо[4',3':4,5]тієно[2,3-d]піримідину
EP3434674B1 (en) ((4-(2-oxoimidazolidine-1-yl)pyrimidin-2-yl)amine derivatives as mutant idh inhibitors for treating cancer
CN112823159B (zh) 一类具有激酶抑制活性的芳香杂环类化合物
KR101859170B1 (ko) 트리아졸 화합물 및 이의 용도
CN118251400A (zh) Axl激酶抑制剂的盐、其制备方法和用途
WO2014020531A1 (en) Imidazo[1,2-b]pyridazin-6-amine derivatives as kinase jak-2 inhibitors
HK1256370A1 (en) 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
PL167014B1 (pl) Sposób wytwarzania nowych pochodnych azolu

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831